New Preclinical and Clinical Approaches to Mesothelioma

Sponsor
Marco Emilio Bianchi
Study ID
NCT06536179
Status
Recruiting
Apply to this trial

Conditions

  • Mesothelioma

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Study Details

This study protocol involves the coordination between UO1 (IRCCS San Raffaele Hospital) and UO2 (Istituto Nazionale Tumori di Napoli - IRCCS G. Pascale) to explore the role of HMGB1 and CXCR4 in cancer treatment and metastasis. UO1 focuses on the role of HMGB1 in inflammation, mesothelioma progression, and tissue repair, as well as developing, in future, possible HMGB1 inhibitors for cancer therapy. UO2 specializes in CXCR4's role in cancer, developing CXCR4 antagonists, and tracking CXCR4-dependent metastasis. The hypothesis is that targeting HMGB1 and CXCR4 pathways will inhibit tumor progression and metastasis, enhancing anti-tumor immunity and improving therapeutic outcomes in cancer.

Key Dates

First listed
Aug 2, 2024
Start date
Jul 25, 2024
Status verified
Jul 2024
Primary completion
Jul 25, 2025
Completion
Jan 25, 2027

Study Design

Enrollment
70 participants (estimated)

Primary Outcome Measure

To set up spheroids models to study and serve as a platform [ Time Frame: 0/baseline ]

Central Contacts

Related Studies